Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach. KU Leuven
Even with today’s ongoing progress in diagnosis and treatment options, HGSOC is still characterized by poor long-term survival and high recurrence rates. Platinum-based chemotherapy and surgery are key in the treatment but development of resistance remains a major clinical problem. Recently, more targeted therapies, such as PARPi have been developed which could help to turn around the ‘one-chemo-fits-all’ approach. This breakthrough can have ...